DK0904064T3 - Orale farmaceutiske præparater indeholdende kønshormoner - Google Patents

Orale farmaceutiske præparater indeholdende kønshormoner

Info

Publication number
DK0904064T3
DK0904064T3 DK97920854T DK97920854T DK0904064T3 DK 0904064 T3 DK0904064 T3 DK 0904064T3 DK 97920854 T DK97920854 T DK 97920854T DK 97920854 T DK97920854 T DK 97920854T DK 0904064 T3 DK0904064 T3 DK 0904064T3
Authority
DK
Denmark
Prior art keywords
sex hormones
pharmaceutical preparations
oral pharmaceutical
preparations containing
surfactant
Prior art date
Application number
DK97920854T
Other languages
English (en)
Inventor
Elizabeth Anne Perry
Susan Gerrard Chandler
Josephine Joan Chri Ferdinando
Original Assignee
Scherer Technologies Inc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Inc R P filed Critical Scherer Technologies Inc R P
Application granted granted Critical
Publication of DK0904064T3 publication Critical patent/DK0904064T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97920854T 1996-04-26 1997-04-28 Orale farmaceutiske præparater indeholdende kønshormoner DK0904064T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9608719.2A GB9608719D0 (en) 1996-04-26 1996-04-26 Pharmaceutical compositions
PCT/GB1997/001247 WO1997040823A1 (en) 1996-04-26 1997-04-28 Oral pharmaceutical compositions containing sex hormones

Publications (1)

Publication Number Publication Date
DK0904064T3 true DK0904064T3 (da) 2001-12-17

Family

ID=10792737

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97920854T DK0904064T3 (da) 1996-04-26 1997-04-28 Orale farmaceutiske præparater indeholdende kønshormoner

Country Status (12)

Country Link
EP (1) EP0904064B1 (da)
JP (1) JP5088804B2 (da)
KR (1) KR100511133B1 (da)
AT (1) ATE207346T1 (da)
AU (1) AU2707497A (da)
DE (1) DE69707669T2 (da)
DK (1) DK0904064T3 (da)
ES (1) ES2164339T3 (da)
GB (1) GB9608719D0 (da)
PT (1) PT904064E (da)
WO (1) WO1997040823A1 (da)
ZA (1) ZA973653B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
WO2002085337A1 (en) 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2000051570A1 (fr) * 1999-02-26 2000-09-08 Shionogi & Co., Ltd. Capsules molles a croquer presentant des proprietes d'administration ameliorees et leur procede de production
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
RU2246296C2 (ru) * 1999-04-01 2005-02-20 Акцо Нобель Н.В. Композиция, включающая ундеканоат тестостерона и касторовое масло
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
HUP0301668A2 (hu) * 2000-08-10 2003-09-29 Delsys Pharmaceutical Corporation Hidrofób hatóanyagok javított szilárd adagolási formái
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
TNSN03139A1 (fr) 2001-06-21 2005-12-23 Pfizer Prod Inc Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
WO2003002095A1 (fr) * 2001-06-28 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Preparation d'une micro-emulsion de type huile-eau
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN1299686C (zh) * 2003-04-03 2007-02-14 上海医药工业研究院 黄体酮半固体骨架制剂的组合物
AU2004229165A1 (en) * 2003-04-17 2004-10-28 Pharmaton S.A. Multi-vitamin and mineral supplement for pregnant women
JP2005047851A (ja) * 2003-07-29 2005-02-24 Nisshin Pharma Inc ユビデカレノン含有組成物
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2006113505A2 (en) * 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
CA2664427C (en) 2006-10-04 2012-06-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
WO2010042499A1 (en) 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
KR101702142B1 (ko) * 2008-10-22 2017-02-03 아유미 세이야쿠 가부시키가이샤 장관 흡수성을 개선하는 의약 조성물
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
CN102711741A (zh) * 2009-11-09 2012-10-03 比利时胶囊公司 递送载体
PL2519230T3 (pl) 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
CN103705462B (zh) * 2010-04-12 2016-08-31 克劳拉斯医疗有限公司 口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
SG184540A1 (en) * 2010-04-12 2012-11-29 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8900631B2 (en) 2011-04-28 2014-12-02 Health Science Funding, LLC Dosage form to increase prasterone bioavailability
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
FR2988609B1 (fr) * 2012-03-30 2015-09-04 Commissariat Energie Atomique Formulation pour l'hormonotherapie
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX393195B (es) 2012-06-18 2025-03-24 Therapeuticsmd Inc Capsula de estradiol soluble para insercion por via vaginal
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105188670B (zh) * 2013-03-15 2018-11-02 马留斯医药有限责任公司 乳液制剂
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3157505B1 (en) * 2014-06-17 2019-07-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) * 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
BR112018069877A2 (pt) * 2016-04-01 2019-02-05 Therapeuticsmd Inc composição farmacêutica de hormônio esteróide
US20170281647A1 (en) * 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
CN111432805B (zh) 2017-11-27 2023-02-17 梅克里内科尼蒂翁公司 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
WO2020203733A1 (ja) * 2019-03-29 2020-10-08 積水化学工業株式会社 コアシェル構造体、製剤、外用薬、テープ剤及び化粧品
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
CN115052606A (zh) * 2020-02-05 2022-09-13 戴尔诺有限公司 包含睾酮的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
GB2626266B (en) 2021-10-08 2026-04-08 Chemo Res S L Oral pharmaceutical compositions of progesterone and estradiol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs

Also Published As

Publication number Publication date
KR100511133B1 (ko) 2006-04-28
JP5088804B2 (ja) 2012-12-05
EP0904064B1 (en) 2001-10-24
DE69707669D1 (de) 2001-11-29
GB9608719D0 (en) 1996-07-03
ZA973653B (en) 1997-11-19
KR20000065025A (ko) 2000-11-06
ATE207346T1 (de) 2001-11-15
PT904064E (pt) 2002-02-28
EP0904064A1 (en) 1999-03-31
AU2707497A (en) 1997-11-19
ES2164339T3 (es) 2002-02-16
DE69707669T2 (de) 2002-07-11
WO1997040823A1 (en) 1997-11-06
JP2000510458A (ja) 2000-08-15

Similar Documents

Publication Publication Date Title
ATE207346T1 (de) Orale pharmazeutische zusammensetzungen mit sexualhormonen
NO20014719D0 (no) Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
US5532002A (en) Gelatin pharmaceutical formulations
ES2168271T3 (es) Composiciones farmaceuticas que contienen ciclosporinas.
ES2101574T3 (es) Composicion administrable por via oral apta para formar una microemulsion.
KR940018091A (ko) 불포화 지방산을 포함하는 처방
TR199900786T2 (xx) Eykoza penta enoik asit ve/veya stearidonik asit i�eren farmas�tik terkipler.
CA2190485A1 (en) Lacrimal gland specific emulsions for topical application to ocular tissue
CN101528196A (zh) 用于生物利用性差的药物的自乳化组合物
AR029615A1 (es) Una formulacion farmaceutica para la administracion oral
NZ512287A (en) Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
AU4862796A (en) Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
ES2180065T3 (es) Formulaciones de uso topico que contienen acetato de vitamina e.
KR930005635A (ko) 약제학적 조성물
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
NZ506579A (en) Palatable oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
RU99106544A (ru) Косметическая композиция
CA2309033A1 (en) Lacrimal gland specific emulsions for topical application to ocular tissue